Orthocell has been featured in AusBiotech’s Spotlight series, which profiles organisations and individuals contributing to Australia’s life sciences sector.

The episode provides an overview of Orthocell’s work as an Australian regenerative medicine company developing medical technologies for bone, nerve and soft tissue repair.

Orthocell’s portfolio includes cell therapies and collagen-based medical devices designed to support surgical repair and guide the body’s natural healing processes. These technologies are used by surgeons to address important unmet clinical needs across tissue reconstruction and repair.

In the episode, Orthocell Managing Director Paul Anderson, Chair John Van Der Wielen and Non-Executive Director Professor Fiona Wood AM discuss the company’s development pathway, including product innovation, manufacturing capability, regulatory approvals and international commercialisation.

The discussion also covers Orthocell’s recent progress in the United States with Remplir^TM and its strategic partnership with BioHorizons, which supports international distribution of the company’s Striate+™ dental bone and tissue regeneration products.

Orthocell thanks AusBiotech for the opportunity to be included in the Spotlight series.